Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judith Lin

Vascular Surgery Detroit, MI Medical Doctor

NPI 1306909932 CMS profile 240313

Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202

Open in the dashboard

General payments

$15,350

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$82,851 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Judith Lin of Detroit, MI is reported in the CMS Open Payments database as having received $15,350 across 81 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $82,851 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82 4
2024 General $262 8
2023 General $9,781 30
2022 General $3,060 17
2021 General $281 5
2020 General $19 1
2019 General $1,864 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judith Lin
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Judith Lin were reported at $82. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Judith Lin Vascular Surgery median Middle half National median
2019 $1,864 $796 $226–$2,363 $163
2020 $19 $348 $118–$1,110 $114
2021 $281 $471 $158–$1,421 $132
2022 $3,060 $725 $222–$2,183 $149
2023 $9,781 $836 $257–$2,440 $160
2024 $262 $909 $252–$2,619 $164
2025 $82 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $8,925 28 payments
  2. Medical Device Business Services, Inc. $2,153 6 payments
  3. Medtronic USA, Inc. $1,653 13 payments
  4. W. L. Gore & Associates, Inc. $1,298 8 payments
  5. Penumbra, Inc. $280 3 payments
  6. Medistim USA, Inc. $238 1 payment
  7. Medtronic Vascular, Inc. $128 2 payments
  8. Shockwave Medical, Inc $121 1 payment
  9. AngioDynamics, Inc. $113 2 payments
  10. Becton, Dickinson and Company $90 2 payments
  11. Other $351 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,655 27 payments
  2. Food and Beverage $2,395 52 payments
  3. Education $299 2 payments
Products named General payments · program years 2019–2025
  1. IN.PACT Admiral $8,491 20 payments
  2. GORE TAG Thoracic Branch Endoprosthesis $568 3 payments
  3. GORE TAG Thoracic Endoprosthesis $477 2 payments
  4. O-ARM-Spine $350 1 payment
  5. SOVEREIGN $307 11 payments
  6. Indigo System $280 3 payments
  7. Endurant $238 3 payments
  8. MiraQ $238 1 payment
  9. ENDURANT IIS $195 5 payments
  10. GORE VIABAHN Endoprosthesis $148 1 payment
  11. Other $997 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

88

Median for Vascular Surgery: 122

Drug cost

$26,830

Median for Vascular Surgery: $14,135

Branded share of claims

63.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $14,775
Xarelto Rivaroxaban Brand 20 $10,872
Cilostazol Generic 32 $786
Clopidogrel Clopidogrel Bisulfate Brand 21 $396

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$62,076

Medicare's payments for the services billed

Medicare patients

182

Average age 72

Services billed

446

81 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 49%
Chronic kidney disease 49%
Diabetes 48%
COPD 35%
Heart failure 31%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record